In the wake of recent violent crimes allegedly linked to psychiatric medications, the Citizens Commission on Human Rights (CCHR) is urging consumers to scrutinize drug labels for warnings about suicide, aggression, and homicidal ideation, and to demand that prescribing physicians explain these risks, even when they are labeled as rare. The call highlights a broader issue: patients should be fully aware of potential side effects before consenting to treatment.
CCHR's decades-long campaign has brought attention to reports of agitation, aggression, suicidal behavior, and homicidal thoughts associated with some psychotropic drugs. Regulatory agencies in the U.S. and abroad have responded by mandating warnings in drug labeling. However, CCHR argues that a warning buried in a package insert is insufficient. Jan Eastgate, president of CCHR International, stated, "A rare warning buried in a package insert is not the same as a doctor explaining the risk to a patient. Listing a side effect as 'rare' does not establish that the patient was told about it, understood it, or agreed to take that risk. Meaningful informed consent requires meaningful disclosure and prescriber accountability."
The legal and professional implications are being debated. Psychiatric Times recently published an article discussing whether psychiatrists should be held responsible for patients' criminal behavior, noting that "a good portion of the public and the media appear to support the defense theory" in a high-profile murder case where psychiatric polypharmacy was cited. The journal concluded that "psychiatry itself may end up on trial."
The legal doctrine of involuntary intoxication may apply when prescribed drugs are alleged to have induced violent behavior, depending on whether the drug was taken as prescribed and whether the person knew of the potential effects. Eastgate emphasized that a judge allowing evidence is not equivalent to a physician warning a patient before the first dose.
This issue is not new. In 2004, the FDA issued a public health advisory on antidepressants, identifying reports of anxiety, agitation, hostility, and aggression. The agency subsequently required boxed warnings on suicidality in children and adolescents, later extended to young adults. CCHR's compilation of international regulatory warnings reveals a dramatic increase: 57 warnings or safety notices since 2004 involving violence, aggression, or hostility, compared to five in 2004—a 1,040% increase. Thirteen of these specifically reference homicidal ideation.
Specific examples include homicidal ideation added to venlafaxine labeling in 2005, a boxed neuropsychiatric warning for bupropion in 2009, a class-wide warning for stimulants in 2023, and esketamine labeling instructing patients to seek help for aggressive or violent behavior. Aripiprazole also lists homicidal ideation as a rare adverse reaction.
CCHR stresses that printing a warning does not ensure a patient has seen or understood it. This concern has influenced public policy, such as a 2026 Tennessee law requiring toxicology testing after violent incidents. CCHR advocates for similar laws nationwide.
Eastgate concluded, "While not all individuals taking a prescription psychotropic drug will become violent or suicidal, they should read these warnings and ask questions before agreeing to treatment. Prescribers should explain potentially serious violent and suicidal adverse effects—including those considered rare—and document that the patient was given the information necessary to make an informed decision."
CCHR, established in 1969 by the Church of Scientology and Dr. Thomas Szasz, maintains that transparent disclosure and prescriber accountability are fundamental to informed consent. Patients are advised not to abruptly stop psychiatric drugs without medical supervision.
